In recent years, multiple probiotics have been tested in randomized controlled trials for IBS (Irritable Bowel Syndrome), but due to differences in strain tested and methodology, making recommendations concerning which probiotics are beneficial for the management of IBS has been difficult to date.
A new well-conducted meta-analysis by renowned gastroenterology experts has been published in the most prominent journal for the field: Gastroenterology, the official journal of the American Gastroenterological Association.
In this study, the authors assessed three endpoints in IBS populations: global symptoms—abdominal pain—bloating, or distension.
Discover the key facts on the study and how S. cerevisiae CNCM I-3856 is now acknowledged as one of the most documented probiotic strains for IBS symptom management, specifically for abdominal pain.
Latest news & videos
- MenaQ7®
- Mobility & Joint
- News
- Apr 09, 2025
Groundbreaking Vitamin K2 Research Presented at the 7th Osteoporosis Congress in Padova (March 19-21, 2025)
Gnosis recently took an important step in advancing the scientific understanding of vitamin K2...
- Emothion®
- News
- Wellness & Immune
- Apr 08, 2025
Emothion® Webinar Explores the Science for Skin Health
Gnosis by Lesaffre recently hosted a highly informative webinar titled "Emothion® Skin Health Redefined:...
- Mobility & Joint
- MyCondro®
- News
- Apr 07, 2025
Discover MyCondro™, The New Brand For Chondroitin Sulfate
Gnosis by Lesaffre reinstates its fermentation-derived chondroitin sulfate under the MyCondro™ brand, previously known...
